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BACKGROUND. The authors assessed adherence with the College of American
Pathologists (CAP) radical prostatectomy (RP) practice protocol in a national
sample of men who underwent RP for early-stage prostate cancer.
METHODS. Using the National Cancer Data Base, the authors identified a nation-
ally representative sample of 1240 men (unweighted) who underwent RP. For
each patient, local cancer registrars performed an explicit medical record review
to assess patient-level compliance with surgical pathology report documentation
of 7 morphologic criteria (ie, quality indicators). Applying the CAP prognostic
factor classification framework, composite measures and all-or-none measures of
quality indicator compliance were calculated for the following analytic categories:
1) a strict subset of CAP category I prognostic factors (3 indicators), 2) a broad
subset of CAP category I factors (6 indicators), and 3) the full set of 7 indicators.
RESULTS. Among a weighted sample of 24,420 patients who underwent RP, com-
pliance with documentation of the CAP category I factors varied from 54% (95%
confidence interval [95% CI], 50–58%) for pathologic tumor, lymph node, metas-
tases classification (according to the American Joint Committee on Cancer sta-
ging system) to 97% (95% CI, 96–99%) for Gleason score. In composite, RP
pathology reports contained 83% (95% CI, 81–84%), 85% (95% CI, 84–87%), and
79% (95% CI, 78–80%) of the recommended data elements measured by the strict
CAP category I subset, the broad CAP category I subset, and the full set of 7 indi-
cators, respectively. In contrast to the generally higher composite scores, only
52% (95% CI, 48–56%) and 41% (95% CI, 37–45%) of men who underwent RP had
complete documentation in their pathology reports for the strict and broad CAP
category I subsets, respectively.
CONCLUSIONS. RP surgical pathology reports contained most of the recom-
mended data elements; however, the frequent absence of pathologic stage pro-
vides an opportunity for quality improvement. Cancer 2007;109:2445–53.  2007
American Cancer Society.
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R ecognizing the need for meticulous clinical communication,1the College of American Pathologists (CAP) endorsed a consen-
sus statement that classifies the prognostic parameters (eg, Gleason
score, margin status) derived from radical prostatectomy (RP) speci-
mens.2–4 Concurrently, the regularly updated CAP prostate cancer
protocol seeks to facilitate systematic, clear, and unambiguous
reporting of prognostically significant pathologic findings from indi-
vidual RP specimens.2–4
In addition to its relevance for individual patients, assessment
and optimization of the quality of pathologic care for men undergoing
RP is recognized today as an important population-level cancer-con-
trol initiative.1,5 The Institute of Medicine’s (IOM) Committee on
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Assessing Improvements in Cancer Care recently iden-
tified the adequacy of RP pathology reports as a useful
metric for the quality of diagnostic prostate cancer
care.6 That committee concurrently highlighted the
paucity of existing data regarding the quality of pathol-
ogy reporting for RP and recommended the American
College of Surgeons’ (ACoS) Commission on Cancer
(CoC)-sponsored studies as a potential source of
benchmark data.6
Coincident with these activities, investigators at
RAND developed a set of quality indicators for early-
stage prostate cancer care.7–9 The RAND indicators
included adherence to the College of American
Pathologists Cancer Committee’s practice protocol
for the management of pathology specimens as a
valid and feasible quality indicator for men under-
going RP for early-stage prostate cancer.7,9
In an effort to build on this complementary work,
the ACoS CoC undertook a special study with the broad
goal of using a subset of the RAND indicators to per-
form the first nationwide assessment of the quality of
care for men with localized prostate cancer.10 One
study objective was to assess pathologic quality indica-
tor compliance in the context of the CAP RP protocol.
This goal was significant, because it provides contem-
porary, nationally representative pathologic bench-
marks that are relevant to ongoing state and national
cancer control endeavors and simultaneously evaluates
the feasibility of using the existing CoC infrastructure
to monitor the quality of pathology reports for oncolo-
gic surgical specimens. In this context, we set out to
determine the quality of pathology reporting for RP
specimens in the U.S.
MATERIALS AND METHODS
The National Cancer Database (NCDB) is a project of
the ACoS, and receives funding for operational support
from the American Cancer Society. The NCDB main-
tains data on cancer diagnosis, management, and out-
comes among patients diagnosed at CoC-approved
programs in the U.S.11 NCDB data are collected from
hospital-based cancer registries using a standardized,
electronic data abstraction format.11 Demographic
characteristics of patients with prostate cancer re-
ported to the NCDB are similar to those in the popula-
tion-based sample maintained by the Surveillance,
Epidemiology, and End Results (SEER) registry.12 From
2000 to 2001, the NCDB collected data for nearly 70%
of incident prostate cancer cases in the U.S.
Case Selection
For the current study, we sampled existing cases
from the NCDB based on the following a priori inclu-
sion criteria: 1) black or white men diagnosed with
adenocarcinoma of the prostate in 2000 or 2001, and
2) American Joint Committee on Cancer stage I or II
tumors (ie, early-stage or localized disease). Using
these criteria, a de-identified file of 117,953 men
with localized prostate cancer diagnosed during 2000
and 2001 was extracted from the NCDB. From this
population, we selected a 5% stratified, random sam-
ple of cases that comprised equal-sized cells based
on race (2 levels: black and white), U.S. Census divi-
sion (9 levels: New England, Middle Atlantic, South
Atlantic, East North Central, East South Central, West
North Central, West South Central, Mountain, and
Pacific), and CoC categories of approval13 for partici-
pating facilities (3 levels: teaching-research hospitals,
comprehensive cancer centers, and community can-
cer centers). Based on this design, we developed
patient-level sampling weights that represented each
patient’s inverse probability of inclusion in the over-
all (ie, eligible) study sample (n ¼ 5655 men). We
applied the sampling weights in all subsequent anal-
yses to produce nationally representative estimates.
This sampling scheme yielded 5655 eligible men,
and these were submitted to participating facilities
for explicit chart abstraction, including assessment of
quality indicator compliance. The number of patients
selected from any 1 facility ranged from 1 to 30; eli-
gible patients must have received all or part of their
first course of therapy at the reporting facility. The
subsequent case-level response rate was 92.5%,
resulting in an unweighted sample of 5230 men with
early-stage prostate cancer. Among this sample, we
used explicitly collected variables that described can-
cer-specific surgery and surgical approach to identify
men who underwent RP.
Data Abstraction
Given the necessarily large number of individuals
performing data abstraction, we used a pilot-tested,
study-specific chart abstraction instrument to guide
local registrars in their assessment of indicator com-
pliance. In preliminary studies, inter-rater reliability
with a similar chart abstraction tool exceeded 95%.14
We also developed a manual that contained uniform
and explicit instructions for verifying compliance (or
lack thereof) with individual quality indicators. For
all data elements that were not reported previously
to the NCDB, we instructed data abstractors to per-
form an explicit medical record review that included
recollection of certain previously abstracted variables
(eg, treatment type, treatment dates). For an addi-
tional quality control measure, we requested that a
designated physician review the data items in each
report for completeness and validity.
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Pathology Quality Indicators
Developed in 19944 and subsequently updated in 19993
and 2005,2,15 the CAP protocol assists pathologists in
the provision of essential clinical information when
reporting results for RP specimens. The protocol distin-
guishes 3 categories of prognostic factors from the RP
surgical pathology report (Table 1).2,15 Category I prog-
nostic factors (Gleason score; pathologic tumor, lymph
node, and metastases [TNM] stage according to the
American Joint Committee on Cancer [AJCC] classifica-
tion; and surgical margin status) are those for which
the prognostic value and relevance to patient manage-
ment are supported well by the literature. Category II
factors (eg, tumor volume, histologic subtype) com-
prise pathologic findings that show significant promise
as prognostic variables but require additional valida-
tion studies prior to routine clinical use. Category III
factors are histologic findings (eg, perineural and lym-
phovascular invasion) for which there are insufficient
data to support prognostic value.2,15
In the current study, we assessed adherence to
the CAP RP protocol by evaluating surgical pathology
report documentation of the following 7 morpholo-
gic-based criteria: 1) Gleason score, 2) pathologic
stage (TNM), 3) surgical margin status, 4) presence
or absence of seminal vesicle invasion, 5) presence
or absence of capsular invasion, 6) tumor size, and
7) tumor location. We refer to each of these morpho-
logic criteria as quality indicators.
Assessment of Quality Indicator Compliance
To guide abstractors’ assessments, we provided the
following written instructions: ‘‘This item describes
the documentation appearing on the surgical pathol-
ogy report following radical retropubic or perineal
prostatectomy. Indicate whether each of the following
items (Gleason score, pathologic stage, status of surgi-
cal margins, status of seminal vesicles, status of cap-
sular invasion, location of tumor, size of tumor) was
documented on the surgical pathology report’’ (em-
phasis present in instruction manual). Consistent
with established methods for indicator assessment,
failure to document findings (positive or negative) for
an indicator was considered noncompliance.7,9,16,17
Statistical Analysis
Analytic indicator sets
The primary outcome for this study was subject-
level indicator compliance. For analytic purposes,
we defined 3 distinct (but not mutually exclusive)
sets of pathologic quality indicators (Table 1). The
first analytic set comprises the 3 explicitly defined
CAP category I prognostic factors (Gleason score,
pathologic TNM stage, and surgical margin status)
(Table 1).2 We refer to this group as the strict CAP
category I subset. Because tumor location, seminal
vesicle status, and capsular invasion also make
essential contributions to the accurate assignment of
pathologic stage, we combined those criteria with
TABLE 1
Working Definitions for Radical Prostatectomy Pathology Specimen Quality Indicators by College of American Pathologists Prognostic Categories










Pathologic Gleason score Documentation of Gleason score in surgical
pathology report
I Xy X X
Pathologic TNM stage Documentation of pathologic TNM stage in
surgical pathology report
I X X X
Seminal vesicle
involvement
Documentation of seminal vesicle involvement in
surgical pathology report
I{ X X
Capsular invasion Documentation of capsular invasion in surgical
pathology report
I{ X X
Tumor location Documentation of tumor location in surgical pathology
report
I{ X X
Margin status Documentation of surgical margin status in
surgical pathology report
I X X X
Tumor size Documentation of tumor size in surgical pathology report II X
CoC indicates Commission on Cancer; CAP, College of American Pathologists; TNM, the American Joint Committee on Cancer tumor, lymph node, metastases classification system.
* Adapted from Srigley, 20062: Category I indicates well supported by the literature, generally used in routine contemporary patient management; category II, established evidence for predictive/prognostic value
but additional validation required.
y X denotes inclusion in the analytic indicator set defined by the column heading.
{ Classified as CAP category I prognostic factors (herein) based on essential contribution to assignment of pathologic T stage.
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the 3 category I criteria to define a second analytic
indicator set (Table 1). We refer to this group of 6
indicators as the broad CAP category I subset. The
final analytic group comprises the full indicator set
of 7 pathologic criteria assessed in the CoC special
study (Table 1).
Approaches to quality measurement
Nolan and Berwick described 3 different approaches
to measuring compliance with multiple, discrete
measures for the same clinical condition (as in the
current study).18 The first is item-by-item measure-
ment, in which compliance with each measure is
reported separately. For this approach, the individual
quality measure is the unit of analysis; the denomi-
nator is the number of patients in the sample who
are eligible for assessment, and the numerator is the
number of patients with documented compliance.18
The second approach, which is referred to generally
as composite measurement, specifies the entire study
sample as the unit of analysis. Using this approach,
composite performance on multiple elements of care
(eg, reporting of multiple pathologic data elements)
is determined by computing a percentage across all
patients and quality indicators.18 The composite
measurement approach is used by the Centers for
Medicare and Medicaid Services (CMS) in its Hospi-
tal Quality Demonstration Project.18,19 The third ap-
proach is all-or-none measurement, which uses the
individual patient as the unit of analysis.18 Using this
methodology, a compliance percentage is calculated
by specifying an all-or-none rule (eg, a pathology
report must contain all of the recommended data
elements to be compliant) at the patient level. The
all-or-none measurement approach is favored now
by the IOM and CMS, because it better represents
the needs of individual patients.18–20 In the current
study, we used all 3 approaches to assess the quality
of pathology reporting for RP specimens.
Item-by-item measurement. In our first analytic step,
we calculated the item-by-item mean percent com-
pliance (with 95% confidence intervals [95% CIs]) for
each of the 7 measured pathology indicators (Table
1). For each item, the numerator is the number of
pathology reports that contained the relevant data
element, and the denominator is the total number of
cases (ie, pathology reports) evaluated.
Composite measurement. Next, we combined data
across individual patients and indicators to calculate
composite measures of quality indicator compliance.
Specifically, we divided all instances in which review
of a pathology report confirmed adherence with doc-
umentation for an individual indicator (ie, the nu-
merator) by the total number of eligible indicators
across all patients (ie, the denominator). We calcu-
lated composite compliance proportions for the strict
and broad CAP category I analytic sets and for the
full analytic set of 7 indicators.
All-or-none measurement. We also used individual
patients as the unit of analysis to calculate all-or-
none measurements of quality indicator compliance.
Of primary interest, we determined the proportion of
men whose pathology reports achieved complete
compliance with indicator documentation. We
defined complete compliance as documented adher-
ence with all of the indicators in a particular analytic
set. The numerator, therefore, is the number of men
who were compliant with each of the indicators (for
a given analytic indicator set). The denominator for
this calculation is the total number of patients evalu-
ated. For example, the complete compliance propor-
tion for the strict CAP category I subset was
calculated by dividing the total number of men
whose pathology reports contained documentation
for Gleason score, pathologic stage, and surgical mar-
gin status (ie, the numerator) by the total number of
patients evaluated (ie, the denominator). We also
determined the proportion of patients who achieved
compliance with all but 1 indicator in a particular
analytic subset. We performed the all-or-none analy-
ses for the strict and broad CAP category I subsets
and for the full set of 7 indicators.
All results are presented as proportions (with
95% CIs), theoretically ranging in value from 0% to
100%. To obtain national estimates of adherence, we
applied sample weights and the strata variable for all
analyses using SAS software (version 9.1; SAS Insti-
tute, Cary, NC). We perform no hypothesis testing;
therefore, our analyses do not account for potential
clustering of outcomes within hospitals.
RESULTS
Among the national sample of 5230 men (92.5%
case-level response rate) who received early-stage
prostate cancer care at 984 CoC-approved facilities in
2000 or 2001, we identified 1390 men (from 542 facil-
ities) who underwent initial RP. Eliminating 150 men
who were noncompliant with all 7 pathology indica-
tors (whose surgical pathology reports presumably
could not be identified during medical record review)
yielded an unweighted analytic sample size of
1240 men. Application of the sample weights to this
unweighted analytic cohort yielded a weighted
sample of 24,420 patients who underwent surgery.
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Table 2 summarizes the demographic and cancer-
specific characteristics of the RP cohort.
Table 3 presents item-by-item compliance for
the individual pathology indicators. The inclusion of
individual measures in RP pathology reports varied
from 42% (95% CI, 38–46%) for tumor size to 97%
(95% CI, 96–99%) for Gleason score. Among the CAP
category I factors, adherence was lowest for the doc-
umentation of pathologic TNM stage (54%; 95% CI,
50–58%).
Table 4 presents the results for the composite
measurement approach. In this table, we specify the
number of indicators that were included in the com-
posite score for each analytic indicator set, the
weighted number of men who were eligible for com-
pliance assessment within each analytic set, the cor-
responding weighted number of eligible events (ie,
the denominator), and the weighted number of times
TABLE 2
Demographic and Cancer Severity Measures Among 24,420 Men who Underwent Radical Prostatectomy*
Characteristic No. of patients (%)






















Use of neoadjuvant hormone therapy
Yes 2306 (9.5)
No 22,103 (90.5)






Private insurance 5758 (23.6)








Comprehensive community cancer center 9567 (39.2)
Community cancer center 9933 (40.7)
U.S. Census division
New England 1723 (7)
Middle Atlantic 3713 (15.2)
South Atlantic 5118 (21)
East North Central 3797 (15.6)
East South Central 1960 (8)
West North Central 1594 (6.5)
West South Central 2294 (9.4)
Mountain 1033 (4.2)
Pacific 3188 (13.1)
PSA indicates prostate-specific antigen; VA, Veterans Administration.
* Weighted sample.
y There were 12 men with missing age data in the weighted sample.
{ There were 1861 men with missing PSA data in the weighted sample.
§ Clinical stage T1 tumors are nonpalpable cancers that are detected by either PSA screening or incidentally at the time of prostatectomy performed for benign disease.
k Clinical stage T2 tumors are palpable cancers that, based on digital rectal examination, appear to be confined within the prostate gland.
} There were 1237 men with missing Gleason score data in the weighted sample.
# There were 90 men with missing comorbidity data in the weighted sample.
** Based on the American College of Surgeon’s Commission on Cancer Categories of Hospital Approval.13
TABLE 3
Item-by-item Measures of Compliance With Pathology Quality





Gleason score 97.3 (95.9–98.8)
Pathologic TNM stage 54.3 (50.3–58.4)
Surgical margin status 95.7 (94–97.4)
Seminal vesicle status 92.8 (90.6–95.1)
Capsular invasion status 77.4 (74–80.7)
Tumor location 94.1 (92.3–96)
Tumor size 41.9 (38–45.8)
95% CI indicates 95% confidence interval; TNM, the American Joint Committee on Cancer tumor,
lymph node, metastases classification system.
* The denominator for the compliance proportions comprises a weighted sample of 24,420 men who
underwent with radical prostatectomy.
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that indicator compliance was documented. In com-
posite, RP pathology reports contained 83% (95% CI,
81–84%) and 85% (95% CI, 84–87%) of the recom-
mended data elements measured by the strict and
broad CAP category I subsets, respectively (Table 2).
For the full set of 7 pathology indicators, the com-
posite compliance proportion was slightly lower at
79% (95% CI, 78–80%).
Table 5 summarizes the results for the all-or-
none measurement approach. In contrast to the gen-
erally higher composite scores, only 52% (95% CI,
48–56%) and 41% (95% CI, 37–45%) of men who
underwent RP had complete documentation (ie,
complete compliance) in their pathology reports for
the strict and broad CAP category I subsets, respec-
tively (Table 5). When we considered the full indica-
tor set (7 measures), the complete compliance
proportion decreased to 21% (95% CI, 18–25%) (Ta-
ble 5). The pathology reports for 96% of patients
contained documentation for at least 2 of the 3 crite-
ria in the strict CAP category I subset.
DISCUSSION
In this report, we have provided a contemporary
description of the quality of surgical pathology care
reporting for men in the U.S. who undergo RP for
early-stage prostate cancer. Among the 7 morpholo-
gic indicators that we assessed in this study, compli-
ance ranged from 42% for documentation of tumor
size to 97% for documentation of the Gleason score.
For the entire sample, the pathology reports con-
tained 83% of the data elements specified by the
strict CAP category I subset and 79% of recom-
mended data as measured by the full set of 7 patho-
logic indicators. At the patient level, only 52% and
21% of men who underwent RP had pathology
reports that achieved complete compliance with doc-
umentation for the strict CAP category I subset and
the full set of 7 pathology indicators, respectively.
In general, our findings are consistent with the
limited existing literature that evaluates the quality
of pathologic assessment and reporting for RP and
other surgical oncology specimens.16,17,21–23 In a
study of Medicare beneficiaries, Imperato et al.
reported similarly high item-by-item levels of com-
pliance for both surgical margin status (96%) and
Gleason score (97%). Unlike the current study, how-
ever, those authors did not evaluate compliance with
the assignment of pathologic stage.16,17,22 Further-
more, all-or-none measurements (with individual
patients as the unit of analysis) of pathology indica-
tor compliance have not been reported previously;
the less favorable performance on this metric for the
strictly defined CAP category I factors (52%), for
instance, generally reflects the absence of partial
credit18 for cases with documentation of Gleason
score and margin status but not pathologic TNM
stage. Taken together, these data suggest that most
men receive high-quality assessment and communi-
cation of the pathologic findings in their RP speci-
mens. Recognizing, however, that completeness of
pathology reports for both individual items and indi-
vidual patients is the objective,1 a second principal
finding is that opportunities exist to improve surgical
pathology care for men who undergo RP.
Specifically, despite outstanding performance
with respect to both Gleason score (97%) and surgi-
cal margin status (96%), only 54% of pathology
reports contained explicit documentation of the
pathologic TNM stage (the third category I prognos-
tic factor). The less frequent compliance with docu-
mentation of pathologic stage may not be surprising,
because the assignment of a formal TNM stage
requires both the presence and integration of several
data elements, including tumor location, extrapro-
static extension, seminal vesicle invasion, and lymph
TABLE 4















Strict CAP category I indicatorsy 3 24,420 73,260 60,414 82.5 (80.6–84.3)
Broad CAP category I indicators{ 6 24,420 146,520 124,975 85.3 (84.1–86.5)
Full indicator set 7 24,420 170,940 135,199 79.1 (77.8–80.4)
95% CI indicates 95% confidence interval; CAP, College of American Pathologists.
* The denominator comprises 24,420 men who underwent radical prostatectomy multiplied by the number of quality indicators specified in the second column of the corresponding row.
y Strict CAP category I indicators include Gleason score; pathologic American Joint Committee on Cancer tumor, lymph node, metastases (TNM) stage; and surgical margin status.
{ Broad CAP category I indicators include Gleason score, pathologic TNM stage and surgical margin status, seminal vesicle involvement, capsular invasion, and tumor location.
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node status (which may be unknown in the increas-
ingly common scenario in which concurrent pelvic
lymphadenectomy is not performed24). Moreover, we
acknowledge that many of the reports without expli-
cit documentation for pathologic TNM stage con-
tained sufficient data (ie, the remaining elements of
the broad subset of CAP category I factors) to ascer-
tain the pathologic T classification.
At the same time, however, such caveats do not
necessarily justify the omission of pathologic stage
from RP specimen pathology reports.25,26 To be sure,
routine and accurate synthesis and reporting of path-
ologic TNM stage (and its component data elements)
guide evidence-based recommendations for adjuvant
and salvage therapies,2,22,27 precise assessment of
eligibility for clinical trials of emerging therapeutic
protocols,28 communication among clinicians from
different specialties and institutions,1,2 and prognos-
tic group assignment by cancer registrars.25 More-
over, the AJCC guidelines29 specify very few situations
in which a specific T classification, N classification, or
M classification cannot be assigned (even if assign-
ment relies on some combination of clinical judgment
and relevant imaging studies).25 Accordingly, the fre-
quent absence of pathologic stage highlights an op-
portunity to improve the quality of pathology reports
for individual patients who undergo RP.25
Beyond their clinical implications, our findings
are consequential for current population-level cancer
control initiatives.6 For instance, in 2004, the ACoS
CoC modified its accreditation process by requiring
that pathology laboratories at CoC-certified facilities
explicitly report the following scientifically validated
CAP measures for RP specimens: histologic type,
Gleason score, pathologic stage (TNM), surgical mar-
gin status, extraprostatic extension, and seminal vesi-
cle invasion.30 Currently, the CoC is working to
institute a complementary national audit and feed-
back program with the specific objectives of evaluat-
ing and improving the proportion of RP (and other
surgical oncology specimen) pathology reports that
include all of the CAP-recommended data elements.
Data from the current study may provide useful
points of reference for evaluating the success of this
nascent intervention.
It is noteworthy that a Medicare Peer Review
Organization previously demonstrated the feasibility
of using audit and feedback to improve the quality of
RP pathology reports.16,17,22 In a study that was per-
formed in New York, Imperato et al used a coopera-
tive educational program, which included a
performance audit with feedback to hospitals and
pathology laboratory directors, to facilitate improve-
ments in pathology report documentation for 10
quality indicators. After the intervention, compliance
improved for 9 of the 10 measures (range of
improvement, 1.4–23.9%).16,17,22 Despite its success,
that program had several limitations, including its
temporary nature, limited geographic scope, and
inclusion of certain indicators (eg, frozen section
submission) with limited clinical validity. Ideally,
future interventions in this area will employ a sus-
tainable, national infrastructure and will maintain a
primary focus on achieving universal compliance
TABLE 5















compliant with all but 1
quality indicator (95% CI){
Strict CAP category I indicators§ 3 3 (1–3) 52 (47.9–56.1) 96.2 (94.6–97.9)
Broad CAP category I indicatorsk 6 5 (1–6) 41.3 (37.3–45.3) 79.4 (76–82.8)
Full indicator set 7 6 (1–7) 21.4 (18.2–24.6) 55.6 (51.7–59.5)
95% CI indicates 95% confidence interval; CAP, College of American Pathologists.
* For a weighted sample of 24,420 men who underwent radical prostatectomy.
y Complete compliance is defined as compliance with the entire analytic set of indicators specified in a particular row. For the first row, for instance, men for
whom complete compliance was achieved had documentation in the surgical pathology report for all 3 (Gleason score; pathologic American Joint Committee on
Cancer tumor, lymph node, and metastasis [TNM] stage; and margin status) strict CAP category I factors.
{ The proportions presented in this column represent men who achieved compliance with all of the indicators in a given analytic subset or in all but 1 of the
indicators in a given analytic subset.
§ Strict CAP category I indicators include Gleason score, pathologic TNM stage, and surgical margin status.
k Broad CAP category I indicators include Gleason score, pathologic TNM stage and surgical margin status, seminal vesicle involvement, capsular invasion, and
tumor location.
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with documentation of pathologic TNM stage and
the other CAP category I prognostic factors.1,2
Finally, these data may motivate surgeons,
pathologists, laboratories, and hospitals further to
achieve standardization of the basic content of surgi-
cal pathology reports.1,2,31–33 Standardized reporting
has the potential to improve the reliability of patho-
logic data and, in turn, both the quality of clinical
care and the validity of clinical and epidemiologic
research in prostate cancer and other malignancies.1
Directly relevant to this effort, the CAP protocol for
RP specimens is published in checklist form and pro-
vides a standardized, universally available medium
for recording and reporting essential pathologic in-
formation.2,15
The current study has several limitations. First,
although use of the NCDB yields a nationally repre-
sentative sample, the fact that our sampling frame
was limited to CoC-approved hospitals introduces
potential selection bias. That is, unlike nonaccredited
programs, CoC-approved facilities have demon-
strated attainment of a baseline quality threshold
with respect to the provision or availability of basic
clinical and supportive oncology services.13 Accord-
ingly, it is possible that the quality of pathology re-
porting also systematically differs between CoC-
approved and nonapproved facilities.
Next, our reliance on medical record abstraction
to assess levels of indicator compliance raises legiti-
mate concerns regarding the distinction between def-
icits in quality versus deficits in documentation.34–36
Despite this concern, our methodology was based on
the a priori assumption that poor or absent docu-
mentation itself is an indicator of poor quality.7
An additional limitation stems from the largely
consensus-based foundation for several of the pa-
thology quality measures. In the absence of a clear
linkage with specific, favorable outcomes, the
observed variation in compliance with individual
indicators simply may reflect differential interpreta-
tions of the imperfect evidence base supporting the
value of reporting a particular pathologic finding.
Beyond this general concern, the individual qual-
ity indicators have several specific limitations. First,
an important premise of this study is that universal
pathology indicator compliance is both feasible and
desirable for all men who undergo RP. However,
there are noteworthy exceptions to this assumption,
including the consensus that accurate Gleason score
assignment is not possible for patients who receive
neoadjuvant hormone therapy (9.5% of the entire RP
sample, 25% of patients noncompliant with the Glea-
son score indicator).2,37 Although it may be pertinent
to the current study, this concern has limited applic-
ability to quality assessments in more contemporary
RP patients (among whom neoadjuvant hormone
therapy has no established therapeutic benefit and,
thus, its use should be rare).38 Second, compliance
with the surgical margin indicator required only that
the margin status be documented in the surgical pa-
thology report. In contrast, full compliance with the
CAP protocol requires additional documentation of
the location and extent of positive margins.2,15 A
third limitation of the individual indicators is that
there is neither a standard method for measuring tu-
mor volume in RP specimens nor a consensus
regarding the prognostic value of this information.2
Despite these limitations, the current report pro-
vides national data describing the quality of surgical
pathology reports for men who undergo RP for early-
stage prostate cancer. Although, at a population-
level, RP surgical pathology reports contain most of
the recommended data elements, the average patient
has a 50% chance of receiving a pathology report
that is missing clinically important data (ie, a CAP
category I prognostic factor). Our findings suggest
that enhanced communication and documentation
of the pathologic TNM stage may be fruitful targets
for quality-improvement endeavors.
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